Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis

被引：13

作者：

Abdel-Rahman, Omar ^{[1
]}

Fouad, Mona ^{[2
]}

机构：

[1] Ain Shams Univ, Fac Med, Dept Clin Oncol, Cairo, Egypt

[2] Ain Shams Univ, Fac Med, Med Microbiol & Immunol Dept, Cairo, Egypt

来源：

EXPERT REVIEW OF ANTICANCER THERAPY | 2015年 / 15卷 / 04期

关键词：

diarrhea; erlotinib; meta-analysis; NSCLC; stomatitis; RANDOMIZED PHASE-II; 1ST-LINE TREATMENT; 2ND-LINE TREATMENT; OPEN-LABEL; DOUBLE-BLIND; STANDARD CHEMOTHERAPY; TRIAL; MULTICENTER; GEMCITABINE; THERAPY;

D O I：

10.1586/14737140.2015.1014035

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We performed a meta-analysis of diarrhea and stomatitis associated with erlotinib use in patients with advanced non-small cell lung cancer. Eligible studies included randomized trials of patients with non-small cell lung cancer on erlotinib describing events of diarrhea and stomatitis. A total of 19 clinical trials including 7524 patients were considered eligible for the meta-analysis. The relative risk of all-grade diarrhea and stomatitis were 2.96 (95% CI: 2.31-3.8; p < 0.00001), 3.62 (95% CI: 2.43-5.39; p=0.00001), respectively, whereas the relative risk of high-grade diarrhea and stomatitis were 4.65 (95% CI: 3.30-6.55; p < 0.00001), 2.63 (95% CI: 0.83-8.27; p=0.1), respectively. Our meta-analysis has demonstrated that regimens containing erlotinib for the treatment of advanced non-small cell lung cancer are associated with a significantly increased risk of all-grade diarrhea, stomatitis and high-grade diarrhea. Close clinical monitoring is required when using and administering this drug.

引用

页码：465 / 475

页数：11

共 30 条

[1]

Abdelfattah O., 2014, Electrical and Computer Engineering (CCECE), 2014 IEEE 27th Canadian Conference on, P1

[2] Pulmonary toxicities from targeted therapies: a review [J].

Barber, Nicholas A. ;

Ganti, Apar Kishor .

TARGETED ONCOLOGY, 2011, 6 (04) :235-243

[3] Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study [J].

Cappuzzo, Federico ;

Ciuleanu, Tudor ;

Stelmakh, Lilia ;

Cicenas, Saulius ;

Szczesna, Aleksandra ;

Juhasz, Erzsebet ;

Esteban, Emilio ;

Molinier, Olivier ;

Brugger, Wolfram ;

Melezinek, Ivan ;

Klingelschmitt, Gaelle ;

Klughammer, Barbara ;

Giaccone, Giuseppe .

LANCET ONCOLOGY, 2010, 11 (06) :521-529

[4] Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non-small Cell Lung Cancer Patients Aged 70 Years or Older [J].

Chen, Yuh-Min ;

Tsai, Chun-Ming ;

Fan, Wen-Chien ;

Shih, Jen-Fu ;

Liu, Shih-Hao ;

Wu, Chieh-Hung ;

Chou, Teh-Ying ;

Lee, Yu-Chin ;

Perng, Reury-Perng ;

Whang-Peng, Jacqueline .

JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (02) :412-418

[5] Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study [J].

Ciuleanu, Tudor ;

Stelmakh, Lilia ;

Cicenas, Saulius ;

Miliauskas, Skaidrius ;

Grigorescu, Alexandru Calin ;

Hillenbach, Carina ;

Johannsdottir, Hrefna Kristin ;

Klughammer, Barbara ;

Esteban Gonzalez, Emilio .

LANCET ONCOLOGY, 2012, 13 (03) :300-308

[6] Risk of oral and gastrointestinal mucosal injury among patients receiving selected targeted agents: a meta-analysis [J].

Elting, Linda S. ;

Chang, Yu-Chia ;

Parelkar, Pratibha ;

Boers-Doets, Christine B. ;

Michelet, Marisol ;

Hita, Guido ;

Rouleau, Tanya ;

Cooksley, Catherine ;

Halm, Josiah ;

Vithala, Madhuri ;

Bossi, Paolo ;

Escalante, Carmen ;

Brennan, Michael T. .

SUPPORTIVE CARE IN CANCER, 2013, 21 (11) :3243-3254

[7] Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial [J].

Garassino, Marina Chiara ;

Martelli, Olga ;

Broggini, Massimo ;

Farina, Gabriella ;

Veronese, Silvio ;

Rulli, Eliana ;

Bianchi, Filippo ;

Bettini, Anna ;

Longo, Flavia ;

Moscetti, Luca ;

Tomirotti, Maurizio ;

Marabese, Mirko ;

Ganzinelli, Monica ;

Lauricella, Calogero ;

Labianca, Roberto ;

Floriani, Irene ;

Giaccone, Giuseppe ;

Torri, Valter ;

Scanni, Alberto ;

Marsoni, Silvia .

LANCET ONCOLOGY, 2013, 14 (10) :981-988

[8] Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial [J].

Gatzemeier, Ulrich ;

Pluzanska, Anna ;

Szczesna, Aleksandra ;

Kaukel, Eckhard ;

Roubec, Jaromir ;

De Rosa, Flavio ;

Milanowski, Janusz ;

Karnicka-Mlodkowski, Hanna ;

Pesek, Milos ;

Serwatowski, Piotr ;

Ramlau, Rodryg ;

Janaskova, Terezie ;

Vansteenkiste, Johan ;

Strausz, Janos ;

Manikhas, Georgy Moiseevich ;

Von Pawel, Joachim .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) :1545-1552

[9] TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer [J].

Herbst, RS ;

Prager, D ;

Hermann, R ;

Fehrenbacher, L ;

Johnson, BE ;

Sandler, A ;

Kris, MG ;

Tran, HT ;

Klein, P ;

Li, X ;

Ramies, D ;

Johnson, DH ;

Miller, VA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5892-5899

[10] ATLAS: Randomized, Double-Blind, Placebo-Controlled, Phase IIIB Trial Comparing Bevacizumab Therapy With or Without Erlotinib, After Completion of Chemotherapy, With Bevacizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer [J].

Johnson, Bruce E. ;

Kabbinavar, Fairooz ;

Fehrenbacher, Louis ;

Hainsworth, John ;

Kasubhai, Saifuddin ;

Kressel, Bruce ;

Lin, Chin-Yu ;

Marsland, Thomas ;

Patel, Taral ;

Polikoff, Jonathan ;

Rubin, Mark ;

White, Leonard ;

Yang, James Chih-Hsin ;

Bowden, Chris ;

Miller, Vincent .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (31) :3926-+

← 1 2 3 →